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PDZ binding-kinase (PBK) (also named T-lymphokine-activated killer cell-originated protein kinase (TOPK)), a serine/
threonine kinase, is tightly controlled in normal tissues but elevated in many tumors, and functions in tumorigenesis
and metastasis. However, the signaling that regulates expression of PBK in cancer cells remains elusive. Here we show
that atorvastatin (Lipitor), an inhibitor of hydroxymethylglutaryl co-enzyme A (HMG-CoA) reductase that is a rate-limiting
enzyme of mevalonate pathway, down-regulates expression of PBK by impairing protein geranylgeranylation. The shRNA
knockdown demonstrated that Yes-associated protein (YAP) mediates geranylgeranylation-regulated expression of PBK.
Importantly, atorvastatin or the geranylgeranyltransferase I inhibitor GGTI-298 inhibited breast cancer cell proliferation
through inactivation of YAP signaling and down-regulation of PBK. These findings have defined a new signaling pathway
that regulated expression of PBK and identified PBK as a downstream target of the Hippo-YAP signaling, uncoverd a
mechanism underlying the anti-cancer effect by inhibition of mevalonate pathway and geranylgeranylation, and
provided a potential target for breast cancer targeted therapy.
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Breast cancer is the most frequently diagnosed cancer
and the leading cause of cancer death in females world-
wide. Unraveling the molecular and cellular mechanisms
underlying breast cancer progression and metastasis is
necessary for development of therapeutic agents to treat
this disease.
PDZ-binding kinase (PBK) (also named T-lymphokine-
activated killer cell–originated protein kinase (TOPK)) is
a 322 amino acid MAPKK-like serine/threonine protein
kinase that was identified as an interleukin-2 induced
gene in T-lymphokine-activated killer cells and as an
interaction partner with the human tumor suppressor
hDlg [1]. PBK is overexpressed in multiple types of can-
cer, including breast, prostate, colon, bladder, and lung
cancer, but is undetectable in normal tissues except
germ cells in the testis and several fetal tissues [2-5].
PBK mediates UVB-induced JNK activation and facili-
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unless otherwise stated.PBK serves as an oncogenic kinase that exerts positive
feedback on ERK2 to promote colorectal cancer forma-
tion in vitro and in vivo [7]. Furthermore, PBK physically
interacts with the DBD domain of p53 and regulates the
tumor suppressor function of p53 [8]. PBK stimulates
AKT-dependent cell migration/invasion by relieving the
PTEN-dependent suppressive effect, indicating its cru-
cial role in cancer metastasis [9]. PBK phosphorylates
histone H3 at Ser10 in vitro and in vivo, and to function
as molecular marker in breast cancer [10]. Taken to-
gether, overexpression of PBK is correlated with
oncogenesis.
Statins are a class of specific inhibitors of HMG-CoA
reductase, a rate-limiting enzyme in the mevalonate
pathway [11]. The mevalonate pathway is biologically
important because the metabolites of the mevalonate
pathway play vital roles in protein post-translational
modifications such as geranylgeranylation and farnesyla-
tion, cell membrane integrity, respiration electronic
chain reaction, and cholesterol synthesis [12]. As potent
blockers of biosynthesis of cholesterol, statins have longis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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prevent cardiovascular diseases [12]. Because cellular
function of many cell growth signaling molecules, par-
ticularly small GTPases, is dependent on prenylation
that is blocked by statins, treatment of cancer cells with
statins inhibits cell proliferative, migration, and invasion,
and induces apoptosis. Thus, statins become a promising
cancer therapeutic agent against many types of cancers,
including breast cancer [12,13]. It has been demon-
strated that statins trigger tumor-specific apoptosis by
blocking geranylgeranylation of the Rho family GTPase
[12,14], resulting in disorganization of actin stress fibers
[15]. Simvastatin was shown to foster enhanced expres-
sion of mutant p53 to down-regulate CD44 expression,
therefore preventing breast cancer cell metastasis to
bone [16]. Furthermore, simvastatin inactivates NF-κB,
leading to de-repression of PTEN and repression of Bcl-
xl to prevent breast cancer cell growth [17]. Notably, it
was recently demonstrated that the mevalonate pathway
is necessary and sufficient to maintain the malignant
state of breast cancer cells in 3D culture [18]. However,
specific antitumor targets and mechanisms of atorva-
statin (AS) are poorly understood.
The Hippo pathway, with the transcriptional coactiva-
tor Yes-associated protein (YAP) as its downstream
effector, is highly conserved throughout evolution [19].
The mammalian Hippo pathway consists of a core kin-
ase cascade in which MST1/2 (the Hippo analog in
Drosophila) phosphorylates the LATS1/2 kinases (Warts
in Drosophila) [20]. Activated LATS subsequently phos-
phorylates YAP (at Ser127) and its paralog TAZ (at
Ser89) (Yorkie in Drosophila), leading to inactivation of
the transcriptional activity [21-23]. YAP promotes tumor
metastasis through interacting with the TEAD/TEF tran-
scription factors (Scalloped in Drosophila). Increased
YAP/TEAD activity was observed in cancer progression
and metastasis [24]. Upregulation of YAP and its nuclear
localization strongly correlate with poor prognosis and
tumor progression in multiple cancers, including breast
[25], lung, colorectal, ovarian, and liver carcinomas [26].
Overexpression of YAP in a conditional YAP transgenic
mouse model led to tissue overgrowth and tumorigen-
esis [27]. Together, these studies highlight a pivotal role
of the Hippo–YAP pathway in cancer development and
progression.
In this report, we demonstrated that atorvastatin or
the geranylgeranyltransferase (GGTase) I inhibitor
GGTI-298 inhibited proliferation of the estrogen recep-
tor (ER)-negative breast cancer MDA-MB-231 cells and
down-regulated PBK, indicating that PBK is a target
gene of geranylgeranylation signaling. Consistent with
the effect of atorvastatin or GGTI-298, knockdown of
PBK or inhibition of PBK significantly impaired MDA-
MB-231 cell proliferation. Furthermore, we found thatknockdown of YAP down-regulated expression of PBK,
suggesting that PBK is a target gene of YAP. Our studies
therefore identified PBK as a down-stream effector of
geranylgeranylation signaling and a target gene of YAP,
and defined a PBK signaling pathway activated by gera-
nylgeranylation and the Hippo signaling for breast can-
cer growth.Results
Atorvastatin inhibited cell proliferation through inhibition
of geranylgeranyl biosynthesis in ER-negtive (ER-) breast
cancer cells
To examine the effect of statins on breast cancer cell pro-
liferation, we selected two breast cancer cell lines, the ER-
cell line MDA-MB-231 and the ER+ cell line MCF7, in the
experiments. Upon treated with atorvastatin for 48 hrs,
proliferation of the ER- breast cancer MDA-MB-231 cells
was significantly inhibited by about 60% (Figure 1A and B).
Previous studies have shown that inhibition of geranylgera-
nyl biosynthesis is the cause for atorvastatin-induced cyto-
toxicity in breast cancer cells [28]. As shown in Figure 1A
and B, addition of geranylgeraniol to the atorvastatin-
treated cells rescued atorvastatin-caused inhibition of cell
proliferation, confirming that impairing geranylgeranyl bio-
synthesis is the mechanism underlying the atorvastatin-
induced cytotoxicity. Interestingly, atorvastatin had no
significant effect on cell proliferation in the ER+ breast
cancer cell line MCF7 (Figure 1C and D), suggesting that
cell proliferation is independent of geranylgeranyl biosyn-
thesis in MCF7 cells.Atorvastatin down-regulates expression of PBK in MDA-
MB-231 cells but not MCF7 cells
As PBK is a biomarker for poor prognosis in breast cancer
and plays a critical role in mitosis, we wonder if
atorvastatin-induced cytotoxicity involving down-regulation
of PBK gene expression. Consistent with the effect on the
cell proliferation, atorvastatin treatment significantly down-
regulated the mRNA level of PBK in the ER- breast cancer
MDA-MB-231 cells, but not in MCF7 cells (Figure 2A).
Adding geranylgeranyl to atorvastatin-treated MDA-
MB-231 cells rescued down-regulation of PBK mRNA
(Figure 2B). We further examined PBK protein level upon
atorvastatin treatment and rescued by geranylgeranyl
addition. As expected, PBK protein level was significantly
reduced upon atorvastatin treatment and the reduction
was rescued by geranylgeranyl addition in MDA-MB-231
cells (Figure 2C). Interestingly, although PBK protein level
in MCF7 cells is comparable to that in MDA-MB-231
cells, it was not affected by atorvastatin treatment. Taken
together, these data suggest that expression of PBK is
tightly associated with geranylgeranyl-dependent cell pro-







Figure 1 Atorvastatin inhibited cell proliferation through inhibition of geranylgeranyl biosynthesis in MDA-MB-231, an ER-negtive (ER-)
breast cancer cell line. The ER- breast cancer MDA-MB-231 cells or the ER+ breast cancer MCF7 cells were treated with atorvastatin (10 μM) or
atorvastatin (10 μM) plus GGOH (10 μM) for 48 hrs. The cells were photographed under a phase microscope and counted with a hemocytometer.
The proliferation bar graphs were counted from three independent experiments. A and B, MDA-MB-231 cells; C and D, MCF7 cells.
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MDA-MB-231 cells
Although our data indicate that inhibition of geranylger-
anyl biosynthesis is the cause for atorvastatin-induced
cytotoxicity and down-regulation of PBK expression in
MDA-MB-231 cells, the biochemical pathway that is
affected by inhibition of geranylgeranyl biosynthesis is not
determined. Geranylgeranyl pyrophosphate (GGPP), which
is the natural metabolite form of geranylgeranyl in mevalo-
nate pathway, is the substrate of geranylgeranyltransferases
used for protein geranylgeranylation. To test whether
atorvastatin-induced down-regulation of PBK is through
inhibition of geranylgeranylation, we treated MDA-MB-
231 cells with the geranylgeranyltransferase I inhibitor
GGTI-298 and examined PBK protein level in both MDA-
MB-231 and MCF7 cell lysates. As shown in Figure 3A,
GGTI-298 dramatically reduced protein level of PBK in
MDA-MB-231 cells, but not in MCF7 cells, assayed byimmunoblotting. Noticeably, the down-regulatory effect of
GGTI-298 on PBK protein level was stronger than that of
atorvastatin, probably due to incapability of atorvastatin to
eliminate all the geranylgeranyl in the cells. To verify the
down-regulation effect of atorvastatin on PBK expression
in cells, we treated MDA-MB-231 and MCF7 cells with
atorvastatin and monitored changes in the PBK pro-
tein level by immunofluorescent staining. As shown in
Figure 3B, as expected, PBK is localized in nuclei,
which is consistent with its function in nuclei for
phosphorylation of histone H3 [10] and regulation of p53
tumor suppressor activity [8]. Treatment with atorvastatin
caused a significant decrease in PBK staining in MDA-
MB-231 cells (compare panel d with panel a, Figure 3B),
while had no detectable effect on PBK staining in MCF7
cells (compare panel j with panel g, Figure 3B). Taken
together, both immunoblotting and immunofluorescent
staining data clearly indicate that geranylgeranylation
A B
C
Figure 2 Atorvastatin down-regulates expression of PBK in MDA-MB-231 cells but not MCF7 cells. The cells were treated with atorvastatin
(AT) or atorvastatin plus geranylgeraniol(GGOH) for 48 hrs. The effects of atorvastatin and GGOH on expression of PBK mRNA (in A and B) or PBK
protein level (in C) were detected by RT-PCR and immunoblotting respectively.
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ER- breast cancer MDA-MB-231 cells, but not in ER+
breast cancer MCF7 cells.
PBK is the YAP target gene in breast cancer MDA-MB-231
cells
Several recent reports have shown that geranylgeranylation
signaling is mediated by the Hippo-YAP/TAZ pathway for
transcriptional activation and cancer cell proliferation and
migration in MDA-MB-231 cells [28-30]. To confirm this,
we treated MDA-MB-231 cells with GGTI-298 or atorva-
statin for 48 hrs, and examined the effect on nuclear
localization of YAP. Nuclear translocation is an activation
process of YAP [28-30]. As shown in Figure 4, inhibition of
geranylgeranylation by GGTI-298 or atorvastatin elimi-
nated nuclear localization of YAP, indicating that YAP
activation is dependent on geranylgeranylation signaling.
We further examined whether the expression of PBK
is dependent on YAP in MDA-MB-231 cells. As shown
in Figure 5, knockdown of YAP by YAP shRNA signifi-
cantly reduced both mRNA and protein levels of PBK,
indicating that PBK is the target gene of YAP and sug-
gesting that the geranylgeranylation signaling regulates
PBK function through the YAP-mediated transcriptional
activation.
PBK is essential for proliferation of MDA-MB-231 cells
To determine whether PBK mediates the geranylgerany-
lation signaling in breast cancer cell proliferation, we
examined the effect of PBK knockdown and the kinase
inhibition on MDA-MB-231 cell proliferation. As shownin Figure 6A and B, depletion of PBK by PBK shRNA in
MDA-MB-231 cells significantly inhibited cell prolifera-
tion, indicating an important role of PBK in the cancer
cell proliferation. To confirm the PBK knockdown effect,
we employed the PBK kinase inhibitor HI-TOPK-032 to
treat MDA-MB-231 cells for two days and monitored
the effect on cell proliferation. As shown in Figure 6C
and D, inhibition of PBK kinase activity in MDA-MB-
231 cells by 10 μM HI-TOPK-032 caused drastic cell
death. These data suggest that PBK is the protein medi-
ating the geranygeranylation signaling in MDA-MB-231
cell proliferation. Interestingly, we also observed that the
PBK inhibitor HI-TOPK-032 significantly inhibited pro-
liferation of MCF7 cells (data not shown), suggesting
that PBK also plays an important role in proliferation in
MCF7 cells. However, the connection of geranylgerany-
lation signaling to expression of PBK is missing in
MCF7 cells (Figure 3). These data demonstrate that
regulation of expression, not activity, of PBK is the
mechanism underlying geranylgeranylation signaling-
mediated breast cancer cell proliferation.
Discussion
Breast cancer is the leading cause of cancer death in fe-
males worldwide. Unraveling the molecular and cellular
mechanisms underlying breast cancer progression and
metastasis is important for development of targeting
drugs for breast cancer therapy. In this report, we have
shown that atorvastatin inhibits breast cancer cell prolif-
eration through impairing geranylgeranylation. Our data
indicate that geranylgeranylation signaling controls
AB
Figure 3 Geranylgeranylation is required for expression of PBK in MDA-MB-231 cells. A, The cells were treated with atorvastatin (AT) or the
geranylgeranyltransferase I inhibitor GGTI-298 for 48 hrs. The effects of atorvastatin or GGTI-298 on PBK protein level were detected by immunoblotting.
B, MDA-MB-231 or MCF7 cells were treated with DMSO (control) or atorvastatin for 48 hrs. The cells were stained with anti-PBK (green) or DAPI (blue).
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mitosis, thus is important for cancer cell proliferation.
Furthermore, we found that PBK is a target gene of YAP,
a transcription co-activator in the Hippo pathway, suggest-
ing that geranylgeranylation signaling activates YAP to
regulate expression of PBK. Finally, we have shown that
PBK is essential for breast cancer cell proliferation. How-
ever, expression of PBK is responsive to geranylgeranylation
signaling only in ER- breast cancer MDA-MB-231 cells, not
in ER+ breast cancer MCF7 cells. This observation raises a
possibility that linkage of geranylgeranylation signaling to
expression of PBK is established during breast cancer
progression.
Our findings are consistent with recent studies that
discovered the role of geranylgeranylation signaling in
regulating the Hippo-YAP/TAZ pathway for breast can-
cer cell proliferation and migration [28]. The geranylger-
anylation signaling interplays with the Hippo pathway in
regulating YAP/TAZ transcriptional activity. Currently
the geranylgeranylated proteins that transduce signalingto the Hippo-YAP/TAZ pathway have not been identi-
fied. Prenylation, including farnesylation and geranylger-
anylation, is essential for proper localization and activity
of the RAS superfamily of small GTPases and heterotri-
meric G-protein gamma subunit. The Rho GTPase sub-
family is known to be geranylgeranylated and closely
linked to cancer progression [31]. Particularly, RhoA are
thought to play a role in cell proliferation. Recent studies
have shown that GPCR signaling activates RhoA GTPase
that leads to inhibition of the Hippo kinases and activa-
tion of YAP/TAZ [28,32]. We speculate that Rho
GTPase might be the geranylgeranylated protein signal-
ing to the Hippo pathway to activate YAP and expres-
sion of PBK.
Atorvastatin is one of the most popular medicines for
reduction of cholesterol. The anti-breast cancer effect of
atorvastatin has a huge impact on prevention of breast
cancer. Our studies provide fundamental knowledge to
help clinicians to use atorvastatin in breast cancer ther-
apy and prevention. Our data suggest that atorvastatin
Figure 4 Nuclear localization of YAP is inhibited by inhibition of Geranylgeranylation. MDA-MB-231 cells were treated with atorvastatin
(panels d-f) or the geranylgeranyltransferase I inhibitor GGTI-298 (panels g-i) for 48 hrs. The cells were stained with anti-YAP (red) (panels a, d,
and g) or DAPI (blue) (panels b, e, and h).
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cancer cells. The breast cancer cell must have a signaling
context of geranylgeranylation signaling and the Hippo-
YAP/TAZ pathway that confers the effect of atorvastatin
on down-regulation of PBK. In addition, establishment
of linkage of geranylgeranylation signaling to the Hippo-
YAP/TAZ pathway in breast cancer cells seems devel-
oped in breast cancer progression, because our recent
studies found that ER- breast cancer cells are more sen-
sitive to atorvastatin than ER+ breast cancer cells [28].
Thus, statins might be an effective anti-cancer drug for
advanced stage breast cancer. We will further investigate
the role of geranylgeranylation signaling in promoting
cancer progression and validate geranylgeranylation
signaling as a key targeting pathway in advanced breast
cancer therapy.
PBK has been identified as a kinase regulating mitosis
by phosphorylation of GPSM2 (G-protein signaling
modulator 2) in breast cancer cells [33]. PBK also inter-
acts with p53 to regulate expression of cell cycle genes
[8]. Multiple studies have found that PBK overexpresses
in breast, prostate, colon, bladder, and lung cancers and
is a prognostic biomarker for poor outcomes [2-5]. Pre-
vious studies have shown that expression of PBK is regu-
lated by Myc and E2F1 transcriptional factors [34].
Immunofluorescent staining in Figure 3B has shown that
PBK is localized in nuclei, confirming that PBK is a nu-
clear kinase and functions in phosphorylation of nuclear
proteins. Furthermore, our results indicate that PBK is a
target gene of YAP (Figure 5). Interestingly, it has been
observed that E2F1 is also a target gene of YAP [35].
These studies suggest that E2F1 may mediate YAP-
activated expression of PBK in MDA-MB-231 cells.Furthermore, our studies have shown that PBK is con-
nected to geranylgeranylation signaling most likely in
advanced stage breast cancer, and essential for breast
cancer cell proliferation, confirming that PBK is an im-
portant molecular target for breast cancer therapy. Thus,
down-regulation and inhibition of PBK by either target-
ing geranylgeranylation signaling and the Hippo-YAP/
TAZ pathway or directly impairing the kinase activity
are promising approaches for breast cancer therapy,
particularly advanced stage breast cancer therapy.
Conclusions
Inhibition of geranylgeranyl biosynthesis by atorvastatin or
geranylgeranyltransferase I by GGTI-298 significantly re-
duced cell proliferation of the ER-negative breast cancer
MDA-MB-231 cells and down-regulated expression of PBK
in ER-negative breast cancer MDA-MB-231 cells. The
geranylgeranylation-dependent cell proliferation is corre-
lated with geranylgeranylation-dependent PBK expression.
Knockdown of YAP also down-regulated expression of
PBK, indicating that PBK is a target gene of YAP and
suggesting that YAP may mediate geranylgeranylation-
dependent expression of PBK. Direct knockdown of PBK
by shRNA or inhibition of PBK activity by its kinase inhibi-
tor severely impaired breast cancer cell proliferation. Taken
together, we conclude that PBK mediates geranylgeranyla-
tion signaling-promoted breast cancer cell proliferation.
Materials and methods
Materials
Geranylgeraniol (G3278), GGTI-298 (G5169) and HI-
TOPK-032 (SML0796) were purchased from Sigma-






































































Figure 5 PBK is the YAP target gene in breast cancer MDA-MB-231 cells. The YAP shRNA and the lentiviral vector pLKO.1 stable cell lines
were established in MDA-MB-231 cells. The cells were cultured to 90% confluence for extraction of RNA and protein. YAP mRNA and PBK mRNA
were detected by PT-PCR (in A and B). The PBK protein level was detected by immunoblotting of the cell lysates (in C).
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Abcam, anti-Tubulin (G436) from Bioworld, and anti-β-
actin (ac-15) from Sigma.Cell culture
Human kidney cell line HEK293T and human breast
cancer cell lines MCF-7 and MDA-MB-231 were grown
in Dulbecco modified Eagle Medium (DMEM) medium
(HyClone)supplemented with 10% fetal bovine serum
(Excell bio), 100 U/mL penicillin, and 100 mg/mL
streptomycin in 5% CO2 at 37°C. Transfection of plas-
mids was performed with Lipofectin transfection reagent
according to the manufacturer’s protocol.Reverse transcription PCR (RT-PCR) analysis
Total RNA was extracted using RNAiso Plus (TaKaRa)
kit and reverse-transcribed into cDNA by RevertAid
First Strand cDNA Synthesis Kit (TaKaRa) according to
the manufacturer’s instructions. Quantitative PCR ana-
lysis was performed using iTaq Universal SYBR Green
supermix (2×) (BIO-RAD). The primer pairs used for
quantitative PCR are: PBK (human) forward primer: 5′-
CCTTTGGCCTTACTTTGTG -3′; PBK (human) reverse
primer: 5′-ACGATCTTTAGGGTCTTCAT-3′; GAPDH
(human) forward primer: 5′-AACGGATTTGGTCGTAT
TG-3′; GAPDH (human) reverse primer: 5′- GGAAG
ATGGTGATGGGGAT -3′.Preparation of cell lysates and immunoblotting
Culture medium was removed and cells were washed with
cold PBS and lysed in precooled mammalian cell lysis
buffer (40 mM HEPES, pH 7.4, 1% Triton X-100, 100 mM
NaCl, 1 mM EDTA, 25 mM Beta-Glycerolphosphate,
1 mM Na-orthovanadate, 10ug/ml Leupeptin and 10ug/
ml Aprotinin). The SDS-PAGE samples were prepared by
addition of 5 × SDS sample buffer directly to the lysates,
followed by rigorous vortex and denatured at 100°C for
10 min. Electrophoresis was run on 10% NuPAGE Bis-
Tris SDS gels, and separated proteins were transferred
onto Immobilon PVDF-FL (Millipore) membranes.
The membranes were incubated with primary anti-
bodies overnight at 4°C, followed by incubating with
secondary antibodies for 1 h at room temperature. The
protein bands were visualized by Enhanced Chemilu-
minescence Plus reagent (Millipore). The density of
the bands was quantified using Quantity One software
(MiNiCHEMI).Immunofluorescent staining
The cells were cultured in glass coverslip-bottomed
culture dishes (MatTek, Ashland, MA) to 50-80% con-
fluence. After the culture medium was aspirated, the
cells were rinsed with PBS twice, fixed with 3.7% para-
formaldehyde at 25°C for 30 min, and permeabilized






Figure 6 PBK is essential for proliferation of MDA-MB-231 cells. A and B, the PBK shRNA or the vector stable cell line was established in
MDA-MB-231 cells using the tetracycline-induced lentiviral expression system. Expression of the shRNA was induced by doxycycline (1 μg/ml) for
3 days. The knockdown of PBK was detected by immunoblotting (in A), and effects of PBK knockdown on the cell proliferation was examined by
cell counting with a hemacytometer (in B). Data are from at least three independent experiments. C and D, effects of the PBK inhibitor HI-TOPK-
032 on MDA-MB-231 cell proliferation were observed and photographed under a phase microscope (in C) and the proliferation rate was quantified by
cell counting with a hemacytometer (in D). The variation within the triplicate is indicated with the error bars. The proliferation rate is calculated using
the formula PR = (Nt – No)/No, where PR stands for proliferation rate, No for the cell number at seeding, and Nt for the cell number at t time point
after seeding.
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primary antibody at 37°C for 1 h. Then the cells were
washed with TBST three times and incubated with sec-
ondary antibody that was conjugated with a fluorescent
dye at 37°C for 1 h. Finally, the cells were washed with
TBST three times, and the immunofluorescence stain-
ing was visualized under a Nikon inverted fluorescent
microscope. The nuclei were stained with DAPI.
Lentiviral shRNA cloning, production, and infection
Knockdown of PBK or YAP was carried out by infection
of cells with lentiviral vector-loaded shPBK or shYAP.
The PBK shRNA target sequence is CTCTTCTCT
GTATGCACTAAT; and the YAP shRNA targeting se-
quences is CCCAGTTAAATGTTCACCAAT. To pro-
duce the lentiviral particles, the pLKO. 1-tet-puro vector
was co-transfected with the packaging plasmids psPAX2
and pMD2.G into HEK 293 T cells, and the cultured
supernatant containing the viral particles was collected
at 24, 48 and 72 hrs after transfection. This supernatant
was used as the shRNA viral stock solution. For lentiviral
infection, the shRNA viral stock solution was added into
MDA-MB-231 cell culture medium for 24 hrs in the
presence of 4 μg/mL polybrene. In general, the viralinfection efficiency was about 80%. After the infection,
cells were cultured in DMEM plus 10% FBS and 2 μg/ml
puromycin. Selection of puromycin-resistant cell col-
onies was carried out 72 h after transfection. The cell
colonies resistant to puromycin were selected and cul-
tured in DMEM plus 10% FBS, 1 μg/ml tetracycline and
2 μg/ml puromycin. The knockdown efficiency was eval-
uated by detection of protein level with immunoblotting
or mRNA level with qRT-PCR.
Statistical analysis
The experimental data are analyzed statistically using
Student’s t-test for two-treatment comparisons. P < 0.05
is considered as significant.
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